OncoMatch/Clinical Trials/NCT07189065
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Is NCT07189065 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Rocbrutinib and Bendamustine for diffuse large b-cell lymphoma (dlbcl).
Treatment: Rocbrutinib · Bendamustine · Rituximab · Lenalidomide — This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with non-GCB DLBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Endocrine / hormonal
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody-containing regimen
at least one line must include an anti-CD20 antibody-containing regimen
Cannot have received: BTK inhibitor
Previous refractoriness to BTK-targeting drugs
Cannot have received: autologous stem cell transplant
Exception: within 90 days prior to randomization
Patients who have received autologous stem cell transplantation within 90 days prior to randomization
Cannot have received: allogeneic stem cell transplant
patients who have received allogeneic stem cell transplantation
Cannot have received: (Lobertinib)
Previous exposure to Lobertinib
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07189065 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BTK inhibitor, autologous stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify